Roche Reports A "Solid" Third Quarter, But Expects Further EU Pricing Pressure
This article was originally published in The Pink Sheet Daily
Executive SummaryRoche's sales grew only 2% in the first nine months of 2010, held back by U.S. health care reform and EU price cuts, a decline in Tamiflu sales and adverse currency fluctuations.
You may also be interested in...
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.